About BeiGene (NASDAQ:BGNE)
BeiGene, Ltd. is a clinical-stage biopharmaceutical company. The Company is focused in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The Company had used its cancer biology platform to develop four clinical-stage drug candidates, such as BGB-3111, BGB-A317, BGB-290 and BGB-283, as of December 31, 2016. BGB-3111, BGB-290 and BGB-283 are its molecularly targeted agents and is its immuno-oncology agent. BGB-3111 is a potent and highly selective small molecule inhibitor of Bruton's tyrosine kinase (BTK). BGB-283 is a molecule inhibitor of both the monomer and dimer forms of the RAF kinase. BGB-290 is a molecularly targeted, orally available, potent and highly selective inhibitor of the poly ADP ribose polymerase (PARP) family members. BGB-A317 is an investigational humanized monoclonal antibody against the immune checkpoint receptor, PD-1.
Industry, Sector and Symbol:
- Industry: Bio Therapeutic Drugs
- Sub-Industry: N/A
- Sector: Medical
- Symbol: NASDAQ:BGNE
- CUSIP: N/A
- Web: www.beigene.com
- Debt-to-Equity Ratio: 0.20%
- Current Ratio: 9.33%
- Quick Ratio: 8.38%
Sales & Book Value:
- Annual Sales: $1.07 million
- Price / Sales: 3,577.26
- Book Value: $16.81 per share
- Price / Book: 5.01
- Trailing EPS: ($1.30)
- Net Income: ($119,210,000.00)
- Return on Equity: -7.40%
- Return on Assets: -5.44%
- Employees: 322
- Outstanding Shares: 45,470,000
Frequently Asked Questions for BeiGene (NASDAQ:BGNE)
What is BeiGene's stock symbol?
BeiGene trades on the NASDAQ under the ticker symbol "BGNE."
How were BeiGene's earnings last quarter?
BeiGene, Ltd. (NASDAQ:BGNE) announced its quarterly earnings data on Monday, November, 13th. The company reported $2.54 earnings per share for the quarter, topping analysts' consensus estimates of $0.23 by $2.31. The firm earned $220.21 million during the quarter, compared to analysts' expectations of $1.55 million. During the same quarter in the previous year, the firm earned ($1.08) earnings per share. View BeiGene's Earnings History.
Where is BeiGene's stock going? Where will BeiGene's stock price be in 2017?
7 brokers have issued 1 year price targets for BeiGene's shares. Their predictions range from $81.00 to $120.00. On average, they expect BeiGene's stock price to reach $93.00 in the next year. View Analyst Ratings for BeiGene.
What are Wall Street analysts saying about BeiGene stock?
Here are some recent quotes from research analysts about BeiGene stock:
- 1. Cowen and Company analysts commented, "SGMO reported 3Q17 results and is on track to report first data from the Ph1/2 trials." (11/14/2017)
- 2. According to Zacks Investment Research, "BeiGene, Ltd. is a biotechnology company which focused on immuno-oncological therapeutics. The company's clinical-stage drug candidates include BGB-3111, BGB-283, BGB-290, and BGB-A317. BeiGene, Ltd. is based in Camana Bay, Cayman Islands. " (11/13/2017)
- 3. Maxim Group analysts commented, "BeiGene reported 1Q17 results. The company spent $52.5M during the quarter. The increased operating expenses were driven by clinical expansion to pivotal studies. Net loss for the quarter was $50.6M or ($1.27) per share. BeiGene ended the period with $327M of liquidity on the balance sheet. We model rising R&D expenses with clinical advances." (5/11/2017)
Who are some of BeiGene's key competitors?
Some companies that are related to BeiGene include bluebird bio (BLUE), Juno Therapeutics (JUNO), Neurocrine Biosciences (NBIX), Bioverativ (BIVV), Shire-Nps Pharmaceuticals (NPSP), TESARO (TSRO), Sarepta Therapeutics (SRPT), Auspex Pharmaceuticals (ASPX), AveXis (AVXS), Clovis Oncology (CLVS), GW Pharmaceuticals PLC (GWPH), Agios Pharmaceuticals (AGIO), Spark Therapeutics (ONCE), Halozyme Therapeutics (HALO), China Biologic Products (CBPO), Insmed (INSM), Array BioPharma (ARRY) and Loxo Oncology (LOXO).
Who are BeiGene's key executives?
BeiGene's management team includes the folowing people:
- John V Oyler, Chairman of the Board, Chief Executive Officer, Founder (Age 48)
- Howard Liang Ph.D., Chief Financial Officer and Chief Strategy Officer (Age 52)
- Wendy Yan, Senior Vice President, Head of Regulatory Affairs (Age 50)
- Jason Yang M.D.Suffix is Ph.D., Senior Vice President, Head of Clinical Development (Age 51)
- Timothy Y. Chen, Director (Age 59)
- Donald W. Glazer, Director (Age 71)
- Michael J. Goller, Director (Age 40)
- Ranjeev Krishana, Director (Age 41)
- Xiaodong Wang Ph.D., Director (Age 52)
When did BeiGene IPO?
(bgne) raised $126 million in an initial public offering on Wednesday, February 3rd 2016. The company issued 5,500,000 shares at a price of $22.00-$24.00 per share. Goldman Sachs, Morgan Stanley and Cowen and Company served as the underwriters for the IPO and Baird was co-manager.
Who owns BeiGene stock?
BeiGene's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include
(5.60%), Orbimed Advisors LLC (3.28%), Canada Pension Plan Investment Board (1.51%), Brown Advisory Inc. (0.83%), Janus Henderson Group PLC (0.81%) and Myriad Asset Management Ltd. (0.60%). Company insiders that own BeiGene stock include Amy C Peterson, Bros Advisors Lp Baker, Donald W Glazer, Howard Liang, John Oyler, Ruirong Yuan, Thomas Malley and Xiaodong Wang. View Institutional Ownership Trends for BeiGene.
Who sold BeiGene stock? Who is selling BeiGene stock?
BeiGene's stock was sold by a variety of institutional investors in the last quarter, including Artal Group S.A., Brown Advisory Inc., Myriad Asset Management Ltd., Ariose Capital Management Ltd, University of Notre Dame DU Lac and State of New Jersey Common Pension Fund D. Company insiders that have sold BeiGene company stock in the last year include Amy C Peterson, Donald W Glazer, John Oyler and Xiaodong Wang. View Insider Buying and Selling for BeiGene.
Who bought BeiGene stock? Who is buying BeiGene stock?
BeiGene's stock was purchased by a variety of institutional investors in the last quarter, including Canada Pension Plan Investment Board, Janus Henderson Group PLC, California Public Employees Retirement System, Orbimed Advisors LLC, Belpointe Asset Management LLC, First Trust Advisors LP, Westpac Banking Corp and Alps Advisors Inc.. Company insiders that have bought BeiGene stock in the last two years include Bros Advisors Lp Baker, Howard Liang, Ruirong Yuan and Thomas Malley. View Insider Buying and Selling for BeiGene.
How do I buy BeiGene stock?
Shares of BeiGene can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is BeiGene's stock price today?
One share of BeiGene stock can currently be purchased for approximately $84.18.
How big of a company is BeiGene?
BeiGene has a market capitalization of $3.82741 billion and generates $1.07 million in revenue each year. The company earns ($119,210,000.00) in net income (profit) each year or ($1.30) on an earnings per share basis. BeiGene employs 322 workers across the globe.
How can I contact BeiGene?
BeiGene's mailing address is 94 SOLARIS AVENUE CAMANA BAY, GRAND CAYMAN E9, KY1-1108. The company can be reached via phone at 34-59-494-12 or via email at [email protected]
MarketBeat Community Rating for BeiGene (NASDAQ BGNE)MarketBeat's community ratings are surveys of what our community members think about BeiGene and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Analysts' Consensus Rating for BeiGene (NASDAQ:BGNE) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||0 Sell Ratings, 1 Hold Rating, 6 Buy Ratings, 0 Strong Buy Ratings|
|Consensus Rating:||Buy (Score: 2.86)|
|Consensus Price Target: ||$93.00 (10.48% upside)|
Consensus Price Target History for BeiGene (NASDAQ:BGNE)
Analysts' Ratings History for BeiGene (NASDAQ:BGNE)
(Data available from 11/19/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|11/14/2017||Maxim Group||Set Price Target||Buy||$120.00||N/A|
|11/14/2017||Cowen and Company||Reiterated Rating||Buy||N/A|
|11/14/2017||Robert W. Baird||Reiterated Rating||Outperform -> Neutral||$58.00 -> $83.00||N/A|
|10/6/2017||Morgan Stanley||Reiterated Rating||Overweight||$87.00 -> $95.00||N/A|
|8/15/2017||Goldman Sachs Group, Inc. (The)||Reiterated Rating||Buy||$43.00 -> $86.00||Low|
|8/7/2017||Ladenburg Thalmann Financial Services||Initiated Coverage||Buy -> Buy||$81.00||High|
|6/1/2017||William Blair||Reiterated Rating||Outperform||Low|
Earnings History and Estimates Chart for BeiGene (NASDAQ:BGNE)
Earnings History by Quarter for BeiGene (NASDAQ BGNE)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|11/13/2017||Q3||$0.23||$2.54||$1.55 million||$220.21 million||View||N/A|
|3/22/2017||Q4||($0.86)||($1.05)||$3.75 million||$1.00 million||View||N/A|
|8/10/2016||Q2||($0.68)||($0.73)||$2.08 million||$0.40 million||View||N/A|
|3/30/2016||Q4||($1.06)||($3.05)||$1.74 million||$4.68 million||View||N/A|
Earnings Estimates for BeiGene (NASDAQ:BGNE)
2017 EPS Consensus Estimate: ($4.57)
2018 EPS Consensus Estimate: ($7.55)
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for BeiGene (NASDAQ:BGNE)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for BeiGene (NASDAQ BGNE)
Insider Ownership Percentage: 19.90%
Institutional Ownership Percentage: 52.09%
Insider Trades by Quarter for BeiGene (NASDAQ BGNE)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|11/15/2017||John Oyler||CEO||Sell||150,957||$80.50||$12,152,038.50|| |
|11/13/2017||Amy C Peterson||CMO||Sell||3,601||$82.96||$298,738.96|| |
|11/13/2017||John Oyler||CEO||Sell||25,054||$83.06||$2,080,985.24|| |
|8/11/2017||Bros. Advisors Lp Baker||Director||Buy||176,056||$71.00||$12,499,976.00|| |
|7/12/2017||Xiaodong Wang||Director||Sell||20,000||$72.44||$1,448,800.00|| |
|7/10/2017||Donald W Glazer||Director||Sell||10,810||$72.15||$779,941.50|| |
|7/6/2017||John Oyler||CEO||Sell||219,400||$64.82||$14,221,508.00|| |
|6/28/2017||Xiaodong Wang||Director||Sell||35,000||$44.95||$1,573,250.00|| |
|6/23/2017||John Oyler||CEO||Sell||98,500||$44.16||$4,349,760.00|| |
|6/2/2017||Xiaodong Wang||Director||Sell||5,539||$40.00||$221,560.00|| |
|5/4/2017||Xiaodong Wang||Director||Sell||14,461||$40.80||$590,008.80|| |
|5/1/2017||John Oyler||CEO||Sell||36,149||$40.47||$1,462,950.03|| |
|4/5/2017||Xiaodong Wang||Director||Sell||11,650||$36.83||$429,069.50|| |
|3/24/2017||Xiaodong Wang||Director||Sell||38,107||$36.96||$1,408,434.72|| |
|3/20/2017||John Oyler||CEO||Sell||31,989||$39.39||$1,260,046.71|| |
|3/10/2017||Xiaodong Wang||Director||Sell||36,892||$39.89||$1,471,621.88|| |
|3/6/2017||John Oyler||CEO||Sell||108,999||$40.91||$4,459,149.09|| |
|2/27/2017||Xiaodong Wang||Director||Sell||38,351||$38.19||$1,464,624.69|| |
|2/21/2017||John Oyler||CEO||Sell||64,963||$40.55||$2,634,249.65|| |
|11/23/2016||Thomas Malley||Director||Buy||30,000||$32.00||$960,000.00|| |
|11/18/2016||Bros. Advisors Lp Baker||Director||Buy||1,760,495||$32.00||$56,335,840.00|| |
|9/28/2016||Donald W Glazer||Director||Sell||41,463||$30.66||$1,271,255.58|| |
|9/27/2016||Donald W Glazer||Director||Sell||47,149||$29.61||$1,396,081.89|| |
|9/23/2016||Donald W Glazer||Director||Sell||36,443||$31.02||$1,130,461.86|| |
|9/21/2016||Donald W Glazer||Director||Sell||67,252||$31.42||$2,113,057.84|| |
|2/8/2016||Bros. Advisors Lp Baker||Director||Buy||1,912,680||$24.00||$45,904,320.00|| |
|2/8/2016||Howard Liang||CFO||Buy||65,000||$1.85||$120,250.00|| |
|2/8/2016||Ruirong Yuan||Insider||Buy||130,000||$1.85||$240,500.00|| |
Latest Headlines for BeiGene (NASDAQ BGNE)
|$23.00 Million in Sales Expected for BeiGene, Ltd. (BGNE) This Quarter|
www.americanbankingnews.com - November 18 at 11:58 AM
|Q4 2017 Earnings Estimate for BeiGene, Ltd. (BGNE) Issued By William Blair|
www.americanbankingnews.com - November 17 at 10:40 PM
|$0.86 EPS Expected for BeiGene, Ltd. (BGNE) This Quarter|
www.americanbankingnews.com - November 16 at 3:08 AM
|BeiGene, Ltd. (BGNE) CMO Amy C. Peterson Sells 3,601 Shares|
www.americanbankingnews.com - November 15 at 10:29 PM
|BeiGene, Ltd. (BGNE) CEO John Oyler Sells 25,054 Shares|
www.americanbankingnews.com - November 15 at 10:26 PM
|John Oyler Sells 150,957 Shares of BeiGene, Ltd. (BGNE) Stock|
www.americanbankingnews.com - November 15 at 10:26 PM
|BeiGene, Ltd. (BGNE) Stock Rating Reaffirmed by Cowen and Company|
www.americanbankingnews.com - November 14 at 11:03 PM
|BeiGene, Ltd. (BGNE) Rating Lowered to Neutral at Robert W. Baird|
www.americanbankingnews.com - November 14 at 8:46 AM
|BeiGene, Ltd. (BGNE) Announces Earnings Results|
www.americanbankingnews.com - November 14 at 8:20 AM
|BeiGene Reports Third Quarter 2017 Financial Results|
finance.yahoo.com - November 14 at 1:08 AM
|BeiGene Expands Global Pivotal Program for BTK Inhibitor BGB-3111|
finance.yahoo.com - November 14 at 1:08 AM
|BeiGene, Ltd. (BGNE) Rating Lowered to Sell at Zacks Investment Research|
www.americanbankingnews.com - November 13 at 8:30 PM
|BeiGene, Ltd. (BGNE) Receives Average Rating of "Buy" from Analysts|
www.americanbankingnews.com - November 12 at 12:00 PM
|BeiGene Reaches Analyst Target Price|
www.nasdaq.com - November 1 at 5:08 PM
|BeiGene Announces Oral Presentation and Posters at the 59th American Society of Hematology Annual Meeting|
finance.yahoo.com - November 1 at 5:08 PM
|BeiGene, Ltd. (BGNE) to Release Quarterly Earnings on Wednesday|
www.americanbankingnews.com - November 1 at 4:08 AM
|Developments in China's Healthcare Industry|
www.bizjournals.com - October 27 at 11:52 PM
|BeiGene, Ltd. (BGNE) Given Average Rating of "Buy" by Brokerages|
www.americanbankingnews.com - October 18 at 12:48 PM
|BeiGene's (BGNE) Overweight Rating Reaffirmed at Morgan Stanley|
www.americanbankingnews.com - October 7 at 1:04 PM
|[$$] Celgene Invests in Acceleron, BeiGene|
finance.yahoo.com - October 2 at 11:56 AM
|Celgene Invests in Acceleron, BeiGene - Barron's|
www.barrons.com - September 30 at 6:36 PM
|BeiGene, Ltd. (BGNE) PT Raised to $120 at Maxim Group - StreetInsider.com|
www.streetinsider.com - September 30 at 6:36 PM
|BeiGene Presents Preliminary Phase 1 Data for BGB-A317 in Chinese Patients with Advanced Tumors at the 20th Annual Meeting of CSCO|
globenewswire.com - September 28 at 9:48 PM
|BeiGene (BGNE) Presents Preliminary Phase 1 Data for BGB-A317 in Chinese Patients with Advanced Tumors at CSCO|
www.streetinsider.com - September 28 at 9:48 PM
|Maxim Group Reiterates Buy Rating for BeiGene, Ltd. (BGNE)|
www.americanbankingnews.com - September 28 at 2:30 PM
|BeiGene (BGNE) vs. The Competition Head-To-Head Analysis|
www.americanbankingnews.com - September 24 at 2:28 PM
|BeiGene, Ltd. (BGNE) Receives Average Rating of "Buy" from Brokerages|
www.americanbankingnews.com - September 23 at 10:42 AM
|BeiGene Announces Presentation at the 20th Annual Meeting of the Chinese Society of Clinical Oncology|
finance.yahoo.com - September 21 at 4:17 PM
|BeiGene, Ltd. Forecasted to Post Q3 2017 Earnings of ($1.49) Per Share (BGNE)|
www.americanbankingnews.com - September 13 at 8:00 AM
|Checkpoint Inhibitors Are Hot, and CKPT Has Something in the Oven|
finance.yahoo.com - September 12 at 4:45 PM
|[$$] Celgene Launch to Lift BeiGene|
finance.yahoo.com - September 12 at 4:45 PM
|BeiGene Presents Preliminary Phase 1 Data for BGB-A317 in Multiple Solid Tumors at the ESMO 2017 Congress|
finance.yahoo.com - September 11 at 5:09 PM
|Maxim Group Reaffirms Buy Rating for BeiGene, Ltd. (BGNE)|
www.americanbankingnews.com - September 11 at 3:50 PM
|BeiGene (BGNE) Announces Preliminary Phase 1/2 Clinical Data on PARP Inhibitor BGB-290|
www.streetinsider.com - September 8 at 4:55 PM
|BeiGene Presents Preliminary Phase 1/2 Clinical Data on PARP Inhibitor BGB-290 in Patients with Advanced Solid Tumors at the European Society for Medical Oncology 2017 Congress|
finance.yahoo.com - September 8 at 4:55 PM
|BGNE Crosses Above Average Analyst Target|
www.nasdaq.com - September 7 at 9:45 PM
|BeiGene Announces Closing of Global Strategic Oncology Collaboration with Celgene Corporation|
finance.yahoo.com - August 31 at 4:24 PM
|BeiGene to Present at Upcoming Investor Conferences|
finance.yahoo.com - August 30 at 5:47 PM
|BeiGene, Ltd. (BGNE) Given Consensus Rating of "Buy" by Brokerages|
www.americanbankingnews.com - August 29 at 10:46 AM
|Beigene Ltd (BGNE) Rating Reiterated by Goldman Sachs Group, Inc. (The)|
www.americanbankingnews.com - August 15 at 10:32 PM
|BeiGene, Ltd. (BGNE) Director Bros. Advisors Lp Baker Purchases 176,056 Shares|
www.americanbankingnews.com - August 14 at 4:30 PM
|BeiGene (BGNE) Prices of 2.47M Public Offering at $71/ADS|
www.streetinsider.com - August 12 at 4:11 PM
|BeiGene (BGNE) to Offer and Sell $125M ADSs|
www.streetinsider.com - August 11 at 3:49 AM
|BeiGene Announces Pricing of $175 Million Public Offering|
finance.yahoo.com - August 10 at 10:47 PM
|BeiGene Reports Second Quarter 2017 Financial Results|
www.nasdaq.com - August 9 at 4:44 PM
|BeiGene, Ltd. (BGNE) Receives Consensus Recommendation of "Buy" from Brokerages|
www.americanbankingnews.com - August 4 at 1:02 PM
|BeiGene, Ltd. (BGNE) to Release Earnings on Tuesday|
www.americanbankingnews.com - August 1 at 7:30 AM
|How WebMD Got Locked Out Of The China Market|
seekingalpha.com - July 26 at 5:06 PM
|BeiGene, Ltd. (BGNE) Director Xiaodong Wang Sells 20,000 Shares|
www.americanbankingnews.com - July 13 at 7:52 PM
|BeiGene, Ltd. (NASDAQ:BGNE) Director Donald W. Glazer Sells 10,810 Shares|
www.americanbankingnews.com - July 12 at 10:50 PM
BeiGene (NASDAQ BGNE) Chart for Sunday, November, 19, 2017